Therapeutic interventions for advanced prostate cancer (PCa) center on inhibiting androgen
receptor (AR) and downstream signaling pathways. Resistance to androgen deprivation …

Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …

Androgen receptor splice variants are alternatively spliced variants of androgen receptor
that are C-terminally truncated and lack the canonical ligand-binding domain. Accumulating …

Prostate cancer is the second leading cause of cancer-related death in American men.
Although most prostate cancers are initially androgen-dependent and respond to androgen …

Androgen receptor (AR) is a transcription factor that becomes active upon binding to
androgens via its ligand-binding domain (LBD) or in response to signaling cascades …

Simple Summary Androgen receptor splice variants (AR-Vs) play an important role in
prostate cancer progression, especially as a putative resistance mechanism against AR …

Continued androgen receptor (AR) signaling is an established mechanism underlying
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …

Constitutively active androgen receptor splice variants (AR-V) lacking the ligand-binding
domain have been implicated in the pathogenesis of castration-resistant prostate cancer …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Suppression of androgen production and function provides palliation but not cure in men
with prostate cancer (PCa). Therapeutic failure and progression to hormone-refractory PCa …